Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS)

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Matrix metalloproteinases (MMPs) are zinc-dependent enzymes crucial for extracellular matrix degradation and basement membrane integrity.
• MMPs are present in the central and peripheral nervous systems and are implicated in neurological disease pathogenesis, including amyotrophic lateral sclerosis (ALS).
• Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with no effective life-prolonging treatments.

Purpose of the Study:

• To comprehensively review the role of MMPs and their tissue inhibitors (TIMPs) in ALS pathology.
• To evaluate the significance of MMP-2 and MMP-9, along with their inhibitors, as potential biomarkers for ALS.
• To discuss MMPs and TIMPs as potential therapeutic targets for ALS.

Main Methods:

• Literature review of existing research on MMPs, TIMPs, and their involvement in ALS.
• Analysis of proposed hypotheses regarding the role of specific MMPs and TIMPs in ALS pathogenesis.
• Evaluation of the potential of MMPs and TIMPs as diagnostic biomarkers and therapeutic targets.

Main Results:

• Strong evidence suggests MMPs contribute to ALS pathology through direct neurotoxicity or matrix protein degradation, leading to cell death.
• MMP-2 and MMP-9, along with their inhibitors, are highlighted as key players warranting further investigation as potential ALS biomarkers.
• While MMPs are not specific to ALS, their involvement suggests potential therapeutic avenues through selective inhibition.

Conclusions:

• MMPs and TIMPs play a significant role in the complex pathology of ALS.
• MMP-2 and MMP-9 represent promising candidates for ALS biomarker development, pending further validation.
• Targeted inhibition of specific MMPs may offer a future therapeutic strategy for ALS patients, though extensive research is required.